301669-82-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxy Omeprazole is used as an intermediate compound for the development of antacidulant medications. As a metabolite of Omeprazole, it plays a role in the pharmaceutical industry for creating more effective and targeted treatments for acid-related disorders.
Used in Research and Development:
4-Hydroxy Omeprazole serves as a valuable compound for research purposes, particularly in the study of Omeprazole's metabolism and its effects on the human body. Understanding the properties and behavior of this metabolite can contribute to the development of new drugs or the improvement of existing ones.
Used in Quality Control and Analysis:
In the pharmaceutical industry, 4-Hydroxy Omeprazole can be used for quality control and analysis of Omeprazole-based medications. By monitoring the presence and concentration of this metabolite, manufacturers can ensure the efficacy and safety of their products.

InChI:InChI=1/C16H17N3O3S/c1-9-7-17-14(10(2)15(9)22-3)8-23(21)16-18-12-5-4-11(20)6-13(12)19-16/h4-7,20H,8H2,1-3H3,(H,18,19)

Upstream product

• 73590-58-6 omeprazole 

Relevant academic research and scientific papers

Identification and structural characterization of the stress degradation products of omeprazole using Q-TOF-LC-ESI-MS/MS and NMR experiments: Evaluation of the toxicity of the degradation products

Omeprazole (OMP), a prototype proton pump inhibitor used for the treatment of peptic ulcers and gastroesophageal reflux disease (GERD), was subjected to forced degradation studies as per ICH guidelines Q1A (R2). The drug undergoes degradation under acid, base, neutral hydrolysis and oxidative degradation conditions and forms a total of sixteen degradation products, which were characterized by LC-MS/MS experiments and accurate mass measurements. Oxidative degradation products (OMP-15 and OMP-16) were synthesized and confirmed by various NMR experiments. The cytotoxic effects of OMP-15 and OMP-16 were tested on normal human cells HEK 293 and NIH3T3 by MTT assay. Based on the cytotoxicity results, compared to the standard OMP, both OMP-15 and OMP-16 were found to have relatively weaker toxic effects towards normal cells. Further, the in silico toxicity of OMP and its degradation products (OMP-1 to OMP-16) was assessed by the ProTox-II prediction tool. OMP and OMP-8 are predicted to have carcinogenicity, OMP-7 to have hepatotoxicity and OMP-2, OMP-3, OMP-9, OMP-11, OMP-14 and OMP-16 to have immune system toxicity with a high confidence score. The drug, OMP-1, OMP-6, OMP-7, OMP-8, OMP-13 and OMP-15 are predicted to combine with the aryl hydrocarbon receptor (AhR) with a high probability score. Additionally, two different targets, amine oxidase A and prostaglandin G/H synthase 1, are predicted as toxicity targets for OMP, OMP-1, OMP-6, OMP-8, OMP-13, OMP-15 and OMP-16 with probable binding.